CS
HRMY icon

Credit Suisse’s Harmony Biosciences HRMY Stock Holding History

Credit Suisse’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.29M Hold
38,418
– – ﹤0.01% 2115
2023
Q4 		$1.24M Sell
38,418
-1,776
-4% -$49.6K ﹤0.01% 2196
2023
Q3 		$1.32M Buy
40,194
+1,615
+4% +$56.1K ﹤0.01% 2109
2023
Q2 		$1.36M Buy
38,579
+17,768
+85% +$613K ﹤0.01% 2178
2023
Q1 		$679K Buy
20,811
+480
+2% +$21.9K ﹤0.01% 2555
2022
Q4 		$1.12M Sell
20,331
-50
-0.2% -$2.75K ﹤0.01% 2263
2022
Q3 		$901K Buy
20,381
+2,319
+13% +$113K ﹤0.01% 2405
2022
Q2 		$880K Buy
18,062
+6,204
+52% +$279K ﹤0.01% 2479
2022
Q1 		$577K Buy
11,858
+1,367
+13% +$55.8K ﹤0.01% 2892
2021
Q4 		$447K Buy
10,491
+1,121
+12% +$44.7K ﹤0.01% 3899
2021
Q3 		$359K Buy
9,370
+157
+2% +$5.05K ﹤0.01% 4011
2021
Q2 		$260K Buy
+9,213
New +$276K ﹤0.01% 4174

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Credit Suisse's HRMY Position: Q1 2024 in Review

Credit Suisse held its Harmony Biosciences (HRMY) position steady in Q1 2024 at 38,418 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #2115.

Credit Suisse first reported a position in HRMY in Q2 2021 and has held it in 12 quarters since. The position peaked at $1.36M in Q2 2023. 208 funds tracked by Wall St. Rank hold HRMY as of Q1 2024.

  • Credit Suisse held 38,418 shares of Harmony Biosciences worth $1.29M as of Q1 2024.
  • Credit Suisse left its Harmony Biosciences share count unchanged in Q1 2024.
  • Harmony Biosciences made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2115 holding.
  • Credit Suisse first reported a position in Harmony Biosciences in Q2 2021 and has held it in 12 quarters since.
  • Credit Suisse's Harmony Biosciences position peaked at $1.36M in Q2 2023.
  • 208 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.